CRBU Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Caribou Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.60 |
| 52 Week High | US$8.59 |
| 52 Week Low | US$1.54 |
| Beta | 2.43 |
| 11 Month Change | -26.10% |
| 3 Month Change | -64.44% |
| 1 Year Change | -73.06% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.20% |
Recent News & Updates
Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential
Jul 03Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding
Jun 05
Recent updates
Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential
Jul 03Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding
Jun 05Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
Apr 18More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%
Apr 17Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up
Feb 15Caribou Biosciences: Under The Radar With Catalysts Approaching
Feb 01Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans
Jan 10Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues
Nov 18Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Feb 24Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability
Oct 12Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Sep 16Caribou Biosciences: Potential To Change CAR-T Landscape
Aug 01Crispred CAR-T Cells In The Clinic
May 19Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 13Caribou Biosciences: Selling Close To Cash Balance
Apr 26We're Not Very Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Rate
Oct 26Caribou Biosciences: Another Gene Editor Hurt By The Allogene Hold
Oct 12Shareholder Returns
| CRBU | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.8% | -2.3% | 1.0% |
| 1Y | -73.1% | 8.2% | 23.6% |
Return vs Industry: CRBU underperformed the US Biotechs industry which returned 8.2% over the past year.
Return vs Market: CRBU underperformed the US Market which returned 23.6% over the past year.
Price Volatility
| CRBU volatility | |
|---|---|
| CRBU Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CRBU's share price has been volatile over the past 3 months.
Volatility Over Time: CRBU's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 158 | Rachel Haurwitz | cariboubio.com |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.
Caribou Biosciences, Inc. Fundamentals Summary
| CRBU fundamental statistics | |
|---|---|
| Market cap | US$144.51m |
| Earnings (TTM) | -US$115.26m |
| Revenue (TTM) | US$33.40m |
4.3x
P/S Ratio-1.3x
P/E RatioIs CRBU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRBU income statement (TTM) | |
|---|---|
| Revenue | US$33.40m |
| Cost of Revenue | US$120.15m |
| Gross Profit | -US$86.75m |
| Other Expenses | US$28.51m |
| Earnings | -US$115.26m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | -259.70% |
| Net Profit Margin | -345.05% |
| Debt/Equity Ratio | 0% |
How did CRBU perform over the long term?
See historical performance and comparison